Symbol="AUTL"
AssetType="Common Stock"
Name="Autolus Therapeutics Ltd"
Description="Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom."
CIK="1730463"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="FOREST HOUSE, 58 WOOD LANE, WHITE CITY, LONDON, GB"
FiscalYearEnd="September"
LatestQuarter="2023-03-31"
MarketCapitalization="498493000"
EBITDA="-157894000"
PERatio="None"
PEGRatio="None"
BookValue="1.542"
DividendPerShare="0"
DividendYield="0"
EPS="-1.48"
RevenuePerShareTTM="0.065"
ProfitMargin="0"
OperatingMarginTTM="-22.05"
ReturnOnAssetsTTM="-0.25"
ReturnOnEquityTTM="-0.564"
RevenueTTM="7486000"
GrossProfitTTM="-130860000"
DilutedEPSTTM="-1.48"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="6.78"
AnalystTargetPrice="7.31"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="62.1"
PriceToBookRatio="1.046"
EVToRevenue="6.47"
EVToEBITDA="-0.118"
Beta="1.473"
num_52WeekHigh="3.79"
num_52WeekLow="1.6"
num_50DayMovingAverage="2.706"
num_200DayMovingAverage="2.307"
SharesOutstanding="173691000"
DividendDate="None"
ExDividendDate="None"
symbol="AUTL"
open="2.80"
high="2.90"
low="2.72"
price="2.87"
volume="390234.00"
latest_trading_day="2023-07-21"
previous_close="2.73"
change="0.14"
change_percent="5.1282%"
aroon_positive_momentum_days="60"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="60"
Volume_recent_avg="616521"
Change_recent_avg="0.01"
Delta_recent_avg="0.16"
Variance_recent_avg="0.08"
Change_ratio_recent_avg="-0.19"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="60"
Aroon_momentum_negative="40"
image_negative_thumbnail_id_1="164"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0012.jpeg"
image_negative_thumbnail_id_2="1155"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0189.jpeg"
image_neutral_thumbnail_id_1="554"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0045.jpeg"
image_neutral_thumbnail_id_2="555"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0044.jpeg"
image_positive_thumbnail_id_1="662"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0046.jpeg"
image_positive_thumbnail_id_2="707"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0001.jpeg"
image_professor_thumbnail_id_1="1192"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0026.jpeg"
image_professor_thumbnail_id_2="1174"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
